Lantheus Holdings is stepping up its game in the radiopharmaceutical space by acquiring Massachusetts-based Evergreen Theragnostics for $250 million upfront. As part of the deal, which was announced Tuesday morning, Evergreen is also set to receive up to $752.5 million in potential milestone payments for Octevy as well as its clinical and pre-clinical pipeline.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,